The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug ...

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies ...

The FDA has awarded Compass Pathways a priority review voucher and rolling submission for its COMP360 psilocybin therapy for treatment-resistant depression, potentially cutting review time to one or ...

The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...

By Kamal Choudhury and Christy Santhosh April 24 (Reuters) - The U.S. health regulator on Friday moved to speed up the ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is COMPASS Pathways PLC Sponsored ADR (CMPS) one of those stocks right now? A quick ...

Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

Investing.com - Compass Pathways plc (NASDAQ:CMPS) said Thursday the U.S. Food and Drug Administration granted the company a rolling New Drug Application review for COMP360, its synthetic psilocybin ...

In accordance with NASDAQ Listing Rule 5635 (c) (4), the equity awards were approved by the Compensation and Leadership Development Committee of Compass's Board of Directors and were made as a ...